A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

Clinical trial NCT03198650 · COMPLETED

Trial details

NCT number: NCT03198650
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Part1: Advanced B-cell Malignancies Part2: r/rCLL and r/rMCL Part3: Untreated CLL

Start date: 2017-06-27
Primary completion: 2022-10-27
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.